Synthesis. Storage. Physiology and Pathophysiology of Neuromuscular Transmission. Release. Action. Inactivation. Myasthenia Gravis Before

Similar documents
Homeostatic regulation of synaptic strength and the safety factor for neuromuscular transmission

Quantal Analysis Problems

Neuromuscular Junction Testing ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER

Activity Dependent Changes At the Developing Neuromuscular Junction

Cellular Bioelectricity

Alterations in Synaptic Strength Preceding Axon Withdrawal

What effect would an AChE inhibitor have at the neuromuscular junction?

Medicine, University of Lund, Sweden

Neuromuscular Transmission Diomedes E. Logothetis, Ph.D. (Dr. DeSimone s lecture notes revised) Learning Objectives:

SJ Wood and CR Slater. Rachel Armitage

THE NEUROMUSCULAR JUNCTION IN HEALTH AND DISEASE. Practical Exercises: Function and Structure of Neuromuscular Synapses

BIPN100 F15 Human Physiology 1 Lecture 3. Synaptic Transmission p. 1

SYNAPTIC TRANSMISSION 1

BIONB/BME/ECE 4910 Neuronal Simulation Assignments 1, Spring 2013

Papers Form and Function: Homeostatic Regulation of the NMJ. Summary

Acetylcholine. Neuroscience with Pharmacology 2. Neuromuscular Junction 2: Pharmacology. Quaternary nitrogen. Neuromuscular Junction - Pharmacology

Stanley Iyadurai, PhD MD. Assistant Professor of Neurology/Neuromuscular Medicine Nationwide Children s Hospital Myology Course 2015

Compensatory Contribution of Ca V. 2.3 Channels to Acetylcholine Release at the Neuromuscular Junction of Tottering Mice

MYASTHENIA GRAVIS. Mr. D.Raju, M.pharm, Lecturer

CLINICAL PRESENTATION

Mechanisms of the inhibition by neostigmine of tetanic contraction in the mouse diaphragm

Spatial Distribution of Calcium Entry Evoked by Single Action Potentials within the Presynaptic Active Zone

THE NEUROMUSCULAR JUNCTION IN HEALTH AND DISEASE. Biomedical Seminar Room 3, Thursdays 9:30-11:30

THE ANATOMY AND PHYSIOLOGY OF THE NEUROMUSCULAR JUNCTION

Synaptic Transmission

Myasthenia Gravis. Mike Gilchrist 10/30/06

Reliability of neuromuscular transmission and how it is maintained

Chapter 3 subtitles Action potentials

Miniature Excitatory Synaptic Ion Currents in the Earthworm Lumbriterrestris Body Wall Muscles

EE 791 Lecture 2 Jan 19, 2015

amplitude of spontaneous miniature end-plate potentials (m.e.p.p.s).

Effects of adrenaline on nerve terminals in the superior cervical ganglion of the rabbit

Chapter 6 subtitles postsynaptic integration

Biopsychology. Neurons

CHAPTER 44: Neurons and Nervous Systems

PHYSIOLOGY AND PATHOPHYSIOLOGY OF NEUROMUSCULAR TRANSMISSION

NEUROMUSCULAR BLOCKING AGENTS

THE NEUROMUSCULAR JUNCTION IN HEALTH AND DISEASE. Biomedical Seminar Room 5, Mondays 9:30-11:30

Chapter 3 Neurotransmitter release

Electrodiagnosis of Neuromuscular Junction Disorders

Neuroscience 201A (2016) - Problems in Synaptic Physiology

Structure of a Neuron:

Synaptic communication

DOI: /jphysiol The Physiological Society Rapid Report

The action potential travels down both branches because each branch is a typical axon with voltage dependent Na + and K+ channels.

Assessing neuromuscular transmission in mice with Huntington s disease

Synapse Formation. Steven McLoon Department of Neuroscience University of Minnesota

Nerve Muscle Relationship and Neural Muscular Junction Quiz. Remember, you need to know the structure and the function!

Myasthenia gravis. Page 1 of 7

Severely Impaired Neuromuscular Synaptic Transmission Causes Muscle Weakness in the Cacna1a Mutant Mouse Rolling Nagoya

Neurons Chapter 7 2/19/2016. Learning Objectives. Cells of the Nervous System. Cells of the Nervous System. Cells of the Nervous System

Neurons! John A. White Dept. of Bioengineering

Baraa Ayed. Mohammad khatatbeh. 1 P a g e

CONGENITAL MYASTHENIC SYNDROMES: PROGRESS OVER THE PAST DECADE

J. E. ZENGEL and K. L. MAGLEBY From the Department of Physiology and Biophysics, University of Miami School of Medicine, Miami, Florida 33101

THE NEUROMUSCULAR JUNCTION IN HEALTH AND DISEASE. Biomedical Seminar Room 7, Mondays 9:30-11:30

Pharmacology of the Neuromuscular Junction (NMJ)

Critical Illness Polyneuropathy CIP and Critical Illness Myopathy CIM. Andrzej Sladkowski

Is the Stimulation Frequency of the Repetitive Nerve Stimulation Test that You Choose Appropriate?

Supplementary Figure 1. Basic properties of compound EPSPs at

BY K. KUBA From the Department of Physiology, Faculty of Medicine, Kyushu University, Fukuooka, Japan

2/7/16. Ion channel properties

1) Drop off in the Bi 150 box outside Baxter 331 or to the head TA (jcolas).

PHIARMACOLOGICAL ASPECTS OF NEUROMUSCULAR TRANSMIS-

ENHANCEMENT BY AN ANTAGONIST OF TRANSMITTER RELEASE FROM FROG MOTOR NERVE TERMINALS

Principles of Signaling in the Nervous system

photometry on the extruded cytoplasm.

The Journal of Physiology

Bernard Katz ( )

How Synapses Integrate Information and Change

Myasthenia Gravis What is Myasthenia Gravis? Who is at risk of developing MG? Is MG hereditary? What are the symptoms of MG? What causes MG?

Cellular Neurobiology BIPN140

Chapter 8 11/1/2012. Synaptic Components are Ancient. Syncytium or Synapses? Synapse Formation and Function. Early Calcium Spikes

Portions from Chapter 6 CHAPTER 7. The Nervous System: Neurons and Synapses. Chapter 7 Outline. and Supporting Cells

ANSC (FSTC) 607 Physiology and Biochemistry of Muscle as a Food MOTOR INNERVATION AND MUSCLE CONTRACTION

Making sense of Nerve conduction & EMG

Neuromuscular Physiology. Skeletal muscle & Neuromuscular junction

active zones 6neuromuscular junction/freeze-fracture electron microscopy/acetylcholine release/ca2" channels/autoantibodies)

The Therapy of Congenital Myasthenic Syndromes

2401 : Anatomy/Physiology

Archives of. Pharmacology 9 by Springer-Verlag Effects of Guanidine on Synaptic Transmission in the Spinal Cord of the Frog*

BIPN140 Lecture 8: Synaptic Transmission II

Actions of bretylium tosylate at

How Synapses Integrate Information and Change

M yasthenia gravis is a potentially serious

Chapter 5 subtitles GABAergic synaptic transmission

Introduction to Neurobiology

NEUROMUSCULAR TRANSMISSION IN THE LONGITUDINAL LAYER OF SOMATIC MUSCLE IN THE EARTHWORM

INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES

NEURONS COMMUNICATE WITH OTHER CELLS AT SYNAPSES 34.3

Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine - August 11, 2016

increased by about % above the control. Similar increase in Rm (Received 24 October 1974)

Facts about Myasthenia Gravis

Synaptic transmission

NEUROMUSCULAR JUNCTION EFFECTS

Neuromuscular junction in health and disease

5-Nervous system II: Physiology of Neurons

Neuroscience with Pharmacology 2 Functions and Mechanisms of Reflexes. Prof Richard Ribchester

Introduction. Ha Young Shin, Hyung Jun Park, Hyo Eun Lee, Young-Chul Choi, Seung Min Kim. ORIGINAL ARTICLE J Clin Neurol 2014;10(2):

Transcription:

Synthesis Physiology and Pathophysiology of Neuromuscular Transmission Storage Release Action Inactivation Myasthenia gravis and LEMS are autoimmune diseases Myasthenia Gravis Before LEMS: Ca channel antibodies X X X X Case 1 Bilateral ptosis Double vision in all directions Fatiguable weakness Reflexes disappear after exercise Sensation normal MG: AChR antibodies After edrophonium (Tensilon Test) dtc dtc neo sux sux sux neo direct Lambert-Eaton Myasthenic Syndrome Case 2 Weight loss Slurred speech Weak shoulder abduction and hip flexion Reflexes absent, but re-appear after exercise Sensation normal 1

Congenital Myasthenic Syndromes Ca Direct +Ca +4AP +Mg +4AP Direct TTX Palace & Beeson (28) J Neuroimmunol Physiology and Pathophysiology of Neuromuscular Transmission Physiology and Pathophysiology of Neuromuscular Transmission 1. Characteristics of MEPPS and EPPS 2. Quantal analysis 3. Synaptic strength and safety factor 1. Characteristics of MEPPS and EPPS 2. Quantal analysis 3. Synaptic strength and safety factor Amplitude Mini analysis Interval Desaki & Uehara, 1981 Fatt & Katz, 1952, JPhysiol 2

C h. 5 m V C h. 5 m V 5. m s 5. m s C h. C h. 5 m V 5 m V 5. m s 5. m s Measuring EPP s. Typically-measured characteristics of the EPP (or MEPP) Rise Time (1-2 ms) Half-decay Time (2-3 ms) X Action potential add µ-conotoxin add d-tubocurarine Amplitude (1-4 mv) Latency (1-2 ms) Synaptic basal lamina and acetylcholinesterase Anticholinesterases increase EPP amplitude and prolong EPP decay time Control Myasthenia gravis EMG Neostigmine (5 µm) Kosala Dissanayake Intracellular recording - NMJ 3

Physiology and Pathophysiology of Neuromuscular Transmission 1. Characteristics of MEPPS and EPPS 2. Quantal analysis 3. Synaptic strength and safety factor The neuromuscular junction... [is] an experimentally favourable object whose study could throw considerable light on synaptic mechanisms elsewhere Sir Bernard Katz, Fenn Lecture, IUPS Glasgow, 1993 Synaptic recordings from the frog NMJ: B. Katz et al. MEPPs EPPs Desaki & Uehara, 1981, J Neurocytol 1,11 4

EPP s (muscle action potential blocked) EPP s in low Ca/high Mg 4 3 2 Ch Mg 2+ Ca 2+ 1 5 mv 1. ms Action potentials are all-or-nothing signals... but EPPs are variable responses 5 mv 1. ms -5 mv 5. ms Quantal size = Effect of one vesicle release (MEPC/MEPP) Quantal content = Number of vesicles released (EPC/EPP) Binomial model: Binomial model: Let: n=3 p=.17 (q=1-p) m=n.p Let: n=3 p=.17 (q=1-p) m=n.p P() =? P(1) =? P(2) =? P(3) =? P() = q 3 P(1) = 3pq 2 P(2) = 3p 2 q P(3) = p 3 5

P(x) = n! x!(n! x)! p x.q (n! x) Let : x<<n p<<1 Then q (n-x) ~ exp(-np) P(x) = exp(!m). m x Poisson Distribution P() =? P(1) =? P(2) =? P(3) =? x! and n! (n! x)! " n x P(x) = exp(!m). m x Poisson Distribution P() = exp(-m) P(1) = m.exp(-m) P(2) = m 2.exp(-m)/2 P(3) = m 3.exp(-m)/6 x! Frequency 4 3 2 1 Poisson distribution of Quantal Contents of EPPs (n=1 trials) 1 2 3 4 5 6 7 8 9 1 11 12 Quantal content m=1 Poisson distribution of Quantal Contents of EPPs (n=1 trials) Poisson distribution of Quantal Contents of EPPs (n=1 trials) 4 m=2 4 m=3 Frequency 3 2 Frequency 3 2 1 1 1 2 3 4 5 6 7 8 9 1 11 12 Quantal content 1 2 3 4 5 6 7 8 9 1 11 12 Quantal content 6

Poisson distribution of Quantal Contents of EPPs (n=1 trials) Poisson distribution of Quantal Contents of EPPs (n=1 trials) 4 m=4 4 m=5 Frequency 3 2 Frequency 3 2 1 1 1 2 3 4 5 6 7 8 9 1 11 12 Quantal content 1 2 3 4 5 6 7 8 9 1 11 12 Quantal content --> Simulation:Excel God does not play dice Problems - Non-Poisson conditions - MEPP variance - Non-linear summation Problems - Non-Poisson conditions - MEPP variance - Non-linear summation 7

The Normal (Gaussian) Distribution y = exp(!(x! µ) 2 / 2" 2 ) /(" 2# ) y (!x 2 ) # % exp $ & 2".25 y = 5.5 2' (µ = ; σ =.5) x Quantal analysis n + P(x) = " exp(!m) mx.- k =1 x!,- 1 %!( x! kx ) 2 (. 2#k$ 2 ' & 2k$ 2 * )/ MEPP EPP P x = e!m m x x! 1 ' exp (! 3) " 3 x y 15 % ' & ( 1 '! ( x! 1.1k) 2 ( % ' exp # x! $.2 2)k # % 2k.2 2 $ & & ( ( = * % & # # $ $ k = 1 MEPPs m=3 quanta σ=.2 mv x =1.1mv EPPs Stim. Quantal Size: Quantal Content: q = MEPP m = EPP q Methods of quantal analysis: 1. Direct method : m=epp/mepp (better, EPC/MEPPC) 2. Failures method: P()=exp(-m); m=ln(tests/failures) ( for binomial: P()=(1-p) n ) 3. Variance method: m = 1/(C.V.) 2 i.e. m=epp 2 /var(epp) (for binomial: var(m)=npq) Problems - Non-Poisson conditions - MEPP variance - Non-linear summation 8

The ACh null-potential (reversal potential) is about -1 mv 2, channels 2 ms Endplate Current 2 mv Endplate Potential Action Potential EPC s sum linearly : EPP s sum non-linearly V ~ I Desaki & Uehara, 1981, J Neurocytol 1,11 McLachlan EM, Martin AR. Non-linear summation of end-plate potentials in the frog and mouse. J Physiol. 1981 Feb;311:37-24.PMID: 6267255 Correction Factors Martin (1955): v' = v /(1! v /(E m! E r ) m = q(1! v! (E m! E r ) v= EPP amplitude q= MEPP amplitude m = quantal content v' = v /(1! fv(e m! E r ) v! McLachlan & Martin (1981) Where f = an empirically determined ('fudge ) factor Physiology and Pathophysiology of Neuromuscular Transmission 1. Characteristics of MEPPS and EPPS 2. Quantal analysis 3. Synaptic strength and safety factor For mouse muscle, long fibres: f=.8 For frog muscle, long fibres: f=.55 For short muscle fibres (e.g. FDB) the correction is unknown, but f=.3 gives a good fit to our data. 9

Vm 2.5 mv Vm 2.5 mv 1 mv 31 Keyboard AC mv 1 6 1 mv 5 4 3 2 1 mv 1. ms 1. ms 85 9 95 1 15 11 115 12 125 13 135 14 145 5. ms s Vm 2.5 mv 1 mv 1. ms AC mv 1-2 -4-6 -1-8 1 mv 5. ms 19 2 21 22 23 24 25 26 27 28 29 s NMJ size and muscle mibre diameter are correlated The size of NMJ and the extent of junctional folding vary between species Frog Frog Rat Rat Man Man Evoked release and NMJ area are correlated 2 15 1 5 25 5 75 1 125 15 Synaptic area Frog Rat Man Synaptic size-strength regulation compensates for diameter-input resistance nt mf R in = 1 R m R i A! d 3 t! d m V q! R in m! A t 1 mv 2 na 2 ms I = R in MEPPs EPPs Pre- and post-synaptic abnormalities have distinctive effects on EPPs Synaptic Depression Quantal size (q) = response to a single vesicular release (i.e. the amplitude of the spontaneous MEPP) Abnormalities in quantal size indicate a postsynaptic problem - Normal presynaptic function Normal quantal content (impaired postsynaptic function) Quantal content (m) = amount of transmitter released (i.e. the number of synaptic vesicles producing an EPP) Synaptic Facilitation Abnormalities in quantal content indicate a presynaptic problem - Impaired presynaptic function Low quantal content (normal postsynaptic function) 1

Summary of electrophysiological changes in Myasthenia Gravis and Myasthenic Syndrome 5 (NI=Normal Individual) SUMMARY 1. Variation in MEPP interval and EPP amplitude conforms to a Poisson Distribution 2. Quantal content of EPP s can be estimated by Direct, Failures, and Variance Methods. Remember to make allowance, if necessary, for non-linear summation of synaptic potentials 3. Quantal content at rodent NMJ s is about 5 and the safety factor is about 3. 4. Determinants of synaptic strength and safetyfactor at the NMJ include endplate size (CMS), Ca sensitivity (LEMS), ACh receptor density (MG), and muscle fibre size (input resistance.) 11